Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies

Phase 2

Completed

• Conditions: Acute Leukaemia; Myelodysplasia; Chronic Disease; Leukemia; Lymphoma
• Interventions: Drug: Busulfan; Drug: Anti-Thymocyte Globulin; Drug: Fludarabine; Drug: Cyclosporine; Drug: Mycophenolate mofetil

• Registration Number: NCT00795132
• Lead Sponsor: University of Utah

Brief Summary

This is a phase II trial of reduced intensity conditioning with Bu/Flu/ATG in pediatric patients with hematologic malignancies at high risk for transplant related mortality with standard transplantation. Patients qualify based on organ system dysfunction, active but stable infection, history of previous transplant or late stage disease. We plan to enroll 45 patients through the Pediatric Blood and Marrow Transplant Consortium (PBMTC) and anticipate that the outcome of the trial will pave the way for phase II or III disease specific protocols addressing efficacy of the approach compared to standard transplant approaches in better risk patients.

Detailed Description

Summary/Proposal: Reduced Intensity Hematopoietic Cell Transplantation for High-Risk Relapsed Pediatric Hematologic Malignancies and Patients Ineligible for Standard Transplantation We propose a phase II trial of reduced intensity conditioning with Bu/Flu/ATG in pediatric patients with hematologic malignancies at high risk for transplant related mortality with standard transplantation. Patients qualify based on organ system dysfunction, active but stable infection, history of previous transplant, or late stage disease. We plan to enroll 45 patients through the Pediatric Blood and Marrow transplant Consortium (PBMTC) and anticipate that the outcome of the trial will pave the way for phase II or III disease specific protocols addressing efficacy of the approach compared to standard transplant approaches in better risk patients.

Hypothesis High risk pediatric hematologic malignancy patients ineligible for standard myeloablative HCT undergoing reduced intensity conditioning (RIC) HCT can achieve a sustained engraftment rate \> 90% with a 100day TRM \< 30% using either bone marrow or PBSC from related or unrelated donors. High risk pediatric patients undergoing RIC-HCT using related or unrelated cord blood can achieve a sustained engraftment rate \>80% and a 100d TRM \<30%.

Rationale for Reduced Intensity Approaches in High Risk Patients There are a number patient-specific risk factors associated with increased transplant related mortality. They can be broadly placed into three categories: pretransplant organ system dysfunction, active infections at the time of transplant, and degree of pretransplant therapy (previous transplants, third or subsequent remission, etc.).

The primary objective of this study is to determine the likelihood of achieving sustained donor engraftment using reduced intensity conditioning (fludarabine/busulfan/ATG) followed by hematopoietic cell transplantation (HCT) with either cord blood, bone marrow or peripheral blood stem cells (PBMTC) in pediatric patients with hematopoietic malignancies who are at high risk of transplant related mortality (TRM) with myeloablative HCT. Patients qualify based on organ system dysfunction, active but stable infection, history of previous transplant or late stage disease. We plan to enroll 45 patients through the Pediatric Blood and Marrow Transplant Consortium (PBMTC) and anticipate that the outcome of the trial will pave the way for phase II or III disease specific protocols addressing efficacy of the approach compared to standard transplant approaches in better risk patients.

Study procedures Patients receive their conditioning regimen consisting of fludarabine, busulfan, and ATG and then receive their stem cell transplant. Patients receive immunosuppression consisting of cyclosporine and mycophenolate mofetil. Patients with persistent or progressive disease may receive donor lymphocyte infusion off protocol.

Study Timeline

• Study Start: 2004-04
• Study First Submitted: 2008-11-19
• Study First Submitted QC: 2008-11-20
• Study First Posted: 2008-11-21
• Primary Completion: 2009-07
• Study Completion: 2009-07
• Results First Submitted: 2012-01-30
• Results First Submitted QC: 2012-07-11
• Results First Posted: 2012-08-20
• Status Verified: 2013-07
• Last Update Submitted: 2013-07-23
• Last Update Posted: 2013-07-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 47

Inclusion Criteria

1. Patients must be age 21 or younger and must have hematologic malignancies treatable with allogeneic hematopoietic transplantation (acute and chronic leukemias, myelodysplasia or lymphomas, see protocol for further details). Patients qualify for this approach in four ways: 1) presence of organ system dysfunction or severe systemic infections that significantly increase transplant related mortality with standard myeloablative transplant regimens, 2) history of previous myeloablative allogeneic or autologous transplantation, 3) currently in a third or higher CR receiving an unrelated stem cell transplant, or 4) a combination of toxicities that leads the investigator to feel that the child is at high risk (>50%) of TRM. Patients eligible for inclusion based on consideration number 4 above cannot be enrolled unless discussed with the study chair.

2. Organ system dysfunction: at least one of the following organ system dysfunction criteria plus minimum organ function listed in exclusion criteria qualify a patient for treatment on this protocol

   1. Pulmonary: DLCO, FEV1 or TLC/FVC <60% predicted. Patients too young for PFTs with suspected pulmonary toxicity should be assessed by a consulting pulmonologist. If the pulmonologist judges the child to have moderate-severe pulmonary disease they qualify for inclusion.
   2. Renal: creatinine clearance <60ml/m/1.73m2
   3. Hepatic: transaminases >4x normal or total bilirubin >2.0
   4. Cardiac: all patients with suspected cardiac toxicity should undergo a cardiac echo. If the shortening fraction (SF) is <25% a measurement of ejection fraction must be obtained. Patients qualify for reduced intensity therapy if the SF is <25% and the EF <50%.

3. Infections: Patients with responsive but unresolved invasive infections. These infections may be fungal, bacterial or other opportunistic infections. Viral infections do not meet this eligibility criteria.

4. Other patient groups at high risk for transplant related mortality: Patients with a history of a prior allogeneic or autologous transplantation and patients who are in CR3 or greater and receiving an unrelated stem cell transplant are also eligible for this protocol. If the investigator feels that a patient has a combination of risk factors that could increase their risk of transplant related mortality to >50% with standard transplantation they may be eligible for inclusion, but such patients must be reviewed with the protocol chairman prior to enrollment.

Exclusion Criteria

1. Patients must be in a CR (<5% blasts on BM morphology, no active CNS disease, see protocol) with the following exceptions:

   1. AML may proceed with M2 marrow status (<20% blasts).
   2. Lymphoma: residual disease must be responsive and non-bulky (<5cm largest diameter).
   3. Myelodysplasia: Patients with RA, and RAEB are eligible, but RAEB-IT patients are only eligible if treated to <5% blasts (RA) with chemotherapy.
   4. CML-BP must be treated to CR/CP2 to be eligible.

2. Females who are pregnant

3. Patients who are HIV positive or who have other progressive infections

4. Organ dysfunction: patients are ineligible for the following levels of severe organ system dysfunction:

   1. Cardiac: Ejection fraction <30%
   2. Pulmonary: Receiving continuous supplementary oxygen or any of the following: DLCO <30%, FVC/TLC < 30% or FEV1 <30%
   3. Hepatic: patients will be excluded for hepatic synthetic dysfunction evidenced by any of the following: prolongation of the prothrombin time with an INR >2.0, total serum bilirubin >3, or transaminases >10x normal.
   4. Renal: patients with a creatinine clearance <30ml/m/1.73m2 or who require dialysis are not eligible

Donor Eligibility Criteria:

1. Related or unrelated donor who is a 6/6 HLA match at HLA-A, B, and DRB1 locus. 5/6 matches are acceptable with mismatches at class I alleles (A and B), but DRB1 mismatches are not allowed. Intermediate resolution typing of class I and high resolution typing of class II alleles is required. (HLA-C and HLA-DQ matching is encouraged, but not required with the ideal donor matching at 10/10 alleles.)
2. Unrelated cord blood may be used if matched at HLA-A, B and DRB1 at either 4/6, 5/6, or 6/6 antigens. The minimum mononuclear cell dose required for eligibility is 3 x 107 mononuclear cells/kg recipient body weight (based on frozen cell dose). It is strongly suggested that a back up unit of umbilical cord blood be reserved, though not requested, in case of rejection.

Donors must pass required institutional and NMDP health and infectious disease screening.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Unrelated Blood Cord	Fludarabine	Blood Cord donated from a donor unrelated to the participant/recipient
Related BM PBSC	Anti-Thymocyte Globulin	Bone Marrow Peripheral Blood Stem Cell (BM PBSC) from a donor related to the participant/recipient
Unrelated BM PBSC	Anti-Thymocyte Globulin	Bone Marrow Peripheral Blood Stem Cell (BM PBSC) from a donor unrelated to the participant/recipient
Unrelated Blood Cord	Anti-Thymocyte Globulin	Blood Cord donated from a donor unrelated to the participant/recipient
Related BM PBSC	Busulfan	Bone Marrow Peripheral Blood Stem Cell (BM PBSC) from a donor related to the participant/recipient
Related BM PBSC	Fludarabine	Bone Marrow Peripheral Blood Stem Cell (BM PBSC) from a donor related to the participant/recipient
Related BM PBSC	Mycophenolate mofetil	Bone Marrow Peripheral Blood Stem Cell (BM PBSC) from a donor related to the participant/recipient
Related BM PBSC	Cyclosporine	Bone Marrow Peripheral Blood Stem Cell (BM PBSC) from a donor related to the participant/recipient
Unrelated BM PBSC	Busulfan	Bone Marrow Peripheral Blood Stem Cell (BM PBSC) from a donor unrelated to the participant/recipient
Unrelated BM PBSC	Fludarabine	Bone Marrow Peripheral Blood Stem Cell (BM PBSC) from a donor unrelated to the participant/recipient
Unrelated BM PBSC	Cyclosporine	Bone Marrow Peripheral Blood Stem Cell (BM PBSC) from a donor unrelated to the participant/recipient
Unrelated BM PBSC	Mycophenolate mofetil	Bone Marrow Peripheral Blood Stem Cell (BM PBSC) from a donor unrelated to the participant/recipient
Unrelated Blood Cord	Busulfan	Blood Cord donated from a donor unrelated to the participant/recipient
Unrelated Blood Cord	Cyclosporine	Blood Cord donated from a donor unrelated to the participant/recipient
Unrelated Blood Cord	Mycophenolate mofetil	Blood Cord donated from a donor unrelated to the participant/recipient

Primary Outcome Measures

Name	Time	Method
Number of High Risk Pediatric Patients With Successful Sustained Donor Engraftments	24 months	Assessed donor engraftment in very high risk pediatric patients.

Secondary Outcome Measures

Name	Time	Method
Two Year Overall Survival	24 months	The probability that a given patient will be alive two years after transplantation.
Number of Participants Who Experienced Transplantation-related Mortality (TRM)	24 months	Cumulative incidence transplantation-related mortality (TRM)

Trial Locations

Locations (1)

Primary Children's Medical Center; 🇺🇸 Salt Lake City, Utah, United States